Erratum: Metformin reverses multidrug resistance in human hepatocellular carcinoma Bel-7402/5-fluorouracil cells (Mol Med Rep (2014) 10 (2891‑2897) DOI: 10.3892/mmr.2014.2614);Metformin reverses multidrug resistance in human hepatocellular carcinoma Bel-7402/5-fluorouracil cells

Molecular Medicine Reports

Volumn 10, Issue 6, 2014, Pages 2891-2897

  Ling, Sunbin ^a,b   Tian, Yu ^b   Zhang, Haiquan ^b   Jia, Kaiqi ^b   Feng, Tingting ^c   Sun, Deguang ^b   Gao, Zhenming ^b   Xu, Fei ^b   Hou, Zhaoyuan ^b,d   Li, Yan ^b   Wang, Liming ^b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b DALIAN MEDICAL UNIVERSITY   (China)

^c ZHEJIANG CANCER HOSPITAL   (China)

^d SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Hypoxia inducible factor 1 ; Liver neoplasms; Metformin; Multidrug resistance; Multidrug resistance associated protein 1; P glycoprotein

Indexed keywords

MAMMALIA;

FLUOROURACIL; HIF1A PROTEIN, HUMAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; METFORMIN; MTOR PROTEIN, HUMAN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; TARGET OF RAPAMYCIN KINASE;

CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; HUMAN; LIVER NEOPLASMS; METABOLISM; MULTIDRUG RESISTANCE; TUMOR CELL LINE;

AMP-ACTIVATED PROTEIN KINASES; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIVER NEOPLASMS; METFORMIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEINS; TOR SERINE-THREONINE KINASES;

EID: 84914180851     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2022.12691     Document Type: Erratum

References (33)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Carr BI: Hepatocellular carcinoma: Current management and future trends. Gastroenterology 127: S218-S224, 2004.
3. Patt YZ, Hassan MM, Aguayo A, et al: Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma and gallbladder carcinoma. Cancer 101: 578-586, 2004.
4. Lin DY, Lin SM and Liaw YF: Non-surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 12: S319-S328, 1997.
5. Ben Sahra I, Le Marchand-Brustel Y, Tanti JF and Bost F: Metformin in cancer therapy: A new perspective for an old antidiabetic drug? Mol Cancer Ther 9: 1092-1099, 2010.
6. Larsson O, Morita M, Topisirovic I, et al: Distinct perturbation of the translatome by the antidiabetic drug metformin. Proc Natl Acad Sci USA 109: 8977-8982, 2012.
7. Zoncu R, Efeyan A and Sabatini DM: MTOR: From growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12: 21-35, 2011.
8. Wang N, Pan W, Zhu M, et al: Fangchinoline induces autophagic cell death via p53/sestrin2/AMPK signalling in human hepatocellular carcinoma cells. Br J Pharmacol 164: 731-742, 2011.
9. Zhang DM, Liu JS, Deng LJ, et al: Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway. Carcinogenesis 34: 1331-1342, 2013.
10. Cui XD, Lee MJ, Kim JH, et al: Activation of mammalian target of rapamycin complex 1 (mTORC1) and Raf/Pyk2 by growth factor-mediated Eph receptor 2 (EphA2) is required for cholangiocarcinoma growth and metastasis. Hepatology 57: 2248-2260, 2013.
11. Nishikawa T, Takaoka M, Ohara T, et al: Antiproliferative effect of a novel mTOR inhibitor temsirolimus contributes to the prolonged survival of orthotopic esophageal cancer-bearing mice. Cancer Biol Ther 14: 230-236, 2013.
12. Reungwetwattana T, Molina JR, Mandrekar SJ, et al: Brief report: A phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study. J Thorac Oncol 7: 919-922, 2012.
13. Grgic T, Mis L and Hammond JM: Everolimus: A new mammalian target of rapamycin inhibitor for the treatment of advanced renal cell carcinoma. Ann Pharmacother 45: 78-83, 2011.
14. Nakabayashi M, Werner L, Courtney KD, et al: Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer. BJU Int 110: 1729-1735, 2012.
15. Sullivan R, Pare GC, Frederiksen LJ, Semenza GL and Graham CH: Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity. Mol Cancer Ther 7: 1961-1973, 2008.
16. Kunz M and Ibrahim SM: Molecular responses to hypoxia in tumor cells. Mol Cancer 2: 23, 2003.
17. Zhang Y, Liu G, Lin C, Liao G and Tang B: Silencing the EZH2 gene by RNA interference reverses the drug resistance of human hepatic multidrug-resistant cancer cells to 5-Fu. Life Sci 92: 896-902, 2013.
18. Miller RA and Birnbaum MJ: An energetic tale of AMPK-independent effects of metformin. J Clin Invest 120: 2267-2270, 2010.
19. Xiong Y, Lu QJ, Zhao J and Wu GY: Metformin inhibits growth of hepatocellular carcinoma cells by inducing apoptosis via mitochondrion-mediated pathway. Asian Pac J Cancer Prev 13: 3275-3279, 2012.
20. Zhu MM, Tong JL, Xu Q, et al: Increased JNK1 signaling pathway is responsible for ABCG2-mediated multidrug resistance in human colon cancer. PLoS One 7: E41763, 2012.
21. Thomas GV, Tran C, Mellinghoff IK, et al: Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 12: 122-127, 2006.
22. Zhu H, Luo SF, Wang J, et al: Effect of environmental factors on chemoresistance of HepG2 cells by regulating hypoxia-inducible factor-1alpha. Chin Med J (Engl) 125: 1095-1103, 2012.
23. Jin WS, Kong ZL, Shen ZF, Jin YZ, Zhang WK and Chen GF: Regulation of hypoxia inducible factor-1alpha expression by the alteration of redox status in HepG2 cells. J Exp Clin Cancer Res 30: 61, 2011.
24. Takiyama Y, Harumi T, Watanabe J, et al: Tubular injury in a rat model of type 2 diabetes is prevented by metformin: A possible role of HIF-1alpha expression and oxygen metabolism. Diabetes 60: 981-992, 2011.
25. Ece H, Cigdem E, Yuksel K, Ahmet D, Hakan E and Oktay TM: Use of oral antidiabetic drugs (metformin and pioglitazone) in diabetic patients with breast cancer: How does it effect serum Hif-1 alpha and 8Ohdg levels? Asian Pac J Cancer Prev 13: 5143-5148, 2012.
26. Zannella V, Dal Pra A, Muaddi H, et al: Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response. Clin Cancer Res 19: 6741-6750, 2013.
27. Sheng B, Liu J and Li GH: Metformin preconditioning protects Daphnia pulex from lethal hypoxic insult involving AMPK, HIF and mTOR signaling. Comp Biochem Physiol B Biochem Mol Biol 163: 51-58, 2012.
28. Li Y and Ye D: Cancer therapy by targeting hypoxia-inducible factor-1. Curr Cancer Drug Targets 10: 782-796, 2010.
29. Rho JK, Choi YJ, Lee JK, et al: Gefitinib circumvents hypoxia-induced drug resistance by the modulation of HIF-1alpha. Oncol Rep 21: 801-807, 2009.
30. Huang C, Xu D, Xia Q, Wang P, Rong C and Su Y: Reversal of P-glycoprotein-mediated multidrug resistance of human hepatic cancer cells by Astragaloside II. J Pharm Pharmacol 64: 1741-1750, 2012.
31. Ding Z, Yang L, Xie X, et al: Expression and significance of hypoxia-inducible factor-1 alpha and MDR1/P-glycoprotein in human colon carcinoma tissue and cells. J Cancer Res Clin Oncol 136: 1697-1707, 2010.
32. Li DW, Dong P, Wang F, Chen XW, Xu CZ and Zhou L: Hypoxia induced multidrug resistance of laryngeal cancer cells via hypoxia-inducible factor-1alpha. Asian Pac J Cancer Prev 14: 4853-4858, 2013.
33. Chen M, Huang SL, Zhang XQ, et al: Reversal effects of pantoprazole on multidrug resistance in human gastric adenocarcinoma cells by down-regulating the V-ATPases/mTOR/HIF-1alpha/P-gp and MRP1 signaling pathway in vitro and in vivo. J Cell Biochem 113: 2474-2487, 2012.